Featuring perspectives from Dr Bradley J Monk, Dr David M O’Malley, Ms Kathryn M Schlenker and Ms Jaclyn Shaver, moderated by Dr O’Malley, including the following topics:

• Introduction (00:00)
• Overview of Ovarian Cancer (OC) (2:12)
• Role of PARP Inhibitors in Advanced OC (4:56)
• Current and Potential Future Role of Mirvetuximab Soravtansine in OC (28:45)
• Role of Relacorilant in Advanced OC (57:08)
• Utility of Immune Checkpoint Inhibition in Advanced OC (1:14:12)

NCPD information and select publications